In Section A, contributors will receive diverse doses and schedules of oral ABBV-744 pill to determine Safe and sound dosing program. Further members will probably be enrolled in the recognized monotherapy dosign routine. In Section B, contributors will receive oral ruxolitinib and ABBV-744 will likely be specified as "add-on" therapy. https://friedrichk665whs8.blue-blogs.com/profile